✦ LIBER ✦

Subgroup Analysis of US and Non-US Patients in a Global Study of High-Dose Donepezil (23 mg) in Moderate and Severe Alzheimer's Disease

✍ Scribed by Salloway, S.; Mintzer, J.; Cummings, J. L.; Geldmacher, D.; Sun, Y.; Yardley, J.; Mackell, J.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness of donepezil 23 mg in

✍ Knoth, Russell; Bentley, Tanya; Richardson, Sharon; Ramos, Harry 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 52 KB

Efficacy and Safety of Donepezil 23 mg v

✍ Doody, Rachelle S.; Geldmacher, David S.; Farlow, Martin R.; Sun, Yijun; Moline, 📂 Article 📅 2012 🏛 S. Karger AG 🌐 English ⚖ 458 KB

Long-term safety and tolerability of don

✍ Pierre Tariot, Steven Salloway, Jane Yardley, Joan Mackell, Margaret Moline 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 197 KB

Effectiveness and tolerability of high-d

✍ Martin R. Farlow; Stephen Salloway; Pierre N. Tariot; Jane Yardley; Margaret L. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 168 KB

Effect of donepezil 23 mg/day on languag

✍ Ferris, Steven; Mackell, Joan; Bai, Zane; Sun, Yijun 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 80 KB

Long-term safety and tolerability of don

✍ Farlow, Martin; Richardson, Sharon; Mackell, Joan; Sun, Yijun 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 50 KB